Literature DB >> 19773660

Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies.

Marie-Therese Cooney1, Alexandra Dudina, Peter Whincup, Simon Capewell, Alessandro Menotti, Pekka Jousilahti, Inger Njølstad, Raphel Oganov, Troels Thomsen, Aage Tverdal, Hans Wedel, Lars Wilhelmsen, Ian Graham.   

Abstract

BACKGROUND: Options for the prevention of cardiovascular disease, the greatest global cause of death, include population preventive measures (the Rose approach), or specifically seeking out and managing high-risk cases. However, the likely benefit of a population approach has been recently questioned.
OBJECTIVE: To compare the estimated effects of population strategies at varying levels of population-wide risk factor reduction and high-risk strategies at varying rates of screening uptake on cardiovascular disease mortality.
METHODS: Data (of 109 954 participants) were pooled from six European general population cohort studies [the high-risk cohorts from the SCORE (Systematic COronary Risk Evaluation) dataset]. The effects of various population and high-risk strategies for the reduction of risk factors were estimated by calculating the change in 10-year risk of cardiovascular disease mortality (SCORE risk) before and after the particular intervention. Risk factors studied were: total cholesterol, blood pressure and smoking.
RESULTS: At population level, if a 10-year reduction of blood cholesterol level of 10%, a BP reduction of 10% and a 10% reduction in the prevalence of smoking is considered possible, then 9125 lives per million of the population would be saved over 10 years. In contrast, an approach that treats all high-risk individuals with a polypill containing statin, three half-dose antihypertensives and aspirin, with a 20-80% uptake, would save 1861-7452 lives per million. However, the high-risk estimates are very optimistic, as their achievement would require complete compliance.
CONCLUSION: High-risk and population strategies are complementary. These estimates of the benefits of each may be useful to health planners, when combined with their local knowledge. Recently, benefits of population strategies have been underestimated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19773660     DOI: 10.1097/HJR.0b013e32832b38a1

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  34 in total

1.  Fixed-dose combination therapy for the prevention of cardiovascular disease.

Authors:  Angharad N de Cates; Matthew Rb Farr; Karen Rees; Juan P Casas; Mark Huffman
Journal:  Cochrane Database Syst Rev       Date:  2012

Review 2.  CVD screening in low-risk, asymptomatic adults: clinical trials needed.

Authors:  Tamar S Polonsky; Philip Greenland
Journal:  Nat Rev Cardiol       Date:  2012-08-14       Impact factor: 32.419

Review 3.  Risk Stratification for Primary Prevention of Coronary Artery Disease: Roles of C-Reactive Protein and Coronary Artery Calcium.

Authors:  Waqas T Qureshi; Jamal S Rana; Joseph Yeboah; Usama Bin Nasir; Mouaz H Al-Mallah
Journal:  Curr Cardiol Rep       Date:  2015-12       Impact factor: 2.931

Review 4.  Managing sedentary behavior to reduce the risk of diabetes and cardiovascular disease.

Authors:  Paddy C Dempsey; Neville Owen; Stuart J H Biddle; David W Dunstan
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

5.  Personalized Statin Therapy and Coronary Atherosclerotic Plaque Burden in Asymptomatic Low/Intermediate-Risk Individuals.

Authors:  Ranganath Muniyappa; Radwa A Noureldin; Khaled Z Abd-Elmoniem; Riham H El Khouli; Jatin Raj Matta; Ahmed Hamimi; Siri Ranganath; Colleen Hadigan; Lynnette K Nieman; Ahmed M Gharib
Journal:  Cardiorenal Med       Date:  2018-03-26       Impact factor: 2.041

Review 6.  The conundrum of detecting stable angina pectoris in the community setting.

Authors:  Mary Russell; Marie Williams; Esther May; Simon Stewart
Journal:  Nat Rev Cardiol       Date:  2009-12-22       Impact factor: 32.419

7.  Non-invasive volumetric assessment of aortic atheroma: a core laboratory validation using computed tomography angiography.

Authors:  Muhammad Hammadah; Mohammed Qintar; Steven E Nissen; Julie St John; Saqer Alkharabsheh; Motunrayo Mobolaji-Lawal; Femi Philip; Kiyoko Uno; Yu Kataoka; Brett Babb; Roman Poliszczuk; Samir R Kapadia; E Murat Tuzcu; Paul Schoenhagen; Stephen J Nicholls; Rishi Puri
Journal:  Int J Cardiovasc Imaging       Date:  2015-05-12       Impact factor: 2.357

Review 8.  Screening low-risk individuals for coronary artery disease.

Authors:  Chintan S Desai; Roger S Blumenthal; Philip Greenland
Journal:  Curr Atheroscler Rep       Date:  2014-04       Impact factor: 5.113

9.  Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis.

Authors:  Michael D Miedema; Daniel A Duprez; Jeffrey R Misialek; Michael J Blaha; Khurram Nasir; Michael G Silverman; Ron Blankstein; Matthew J Budoff; Philip Greenland; Aaron R Folsom
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-05-06

10.  Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.

Authors:  Joseph Yeboah; Tamar S Polonsky; Rebekah Young; Robyn L McClelland; Joseph C Delaney; Farah Dawood; Michael J Blaha; Michael D Miedema; Christopher T Sibley; J Jeffrey Carr; Gregory L Burke; David C Goff; Bruce M Psaty; Philip Greenland; David M Herrington
Journal:  Circulation       Date:  2015-07-29       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.